Clinical Efficacy of Glucagon Like Peptide-1 (GLP-1) Analogues.

Chun,  Hyun Ji; Kwon,  Hyuk Sang

doi:2013.14.3.125

J Korean Diabetes > Volume 14(3); 2013 > Article

Focused Issue

The Journal of Korean Diabetes 2013;14(3):125-127.
DOI: https://doi.org/10.4093/jkd.2013.14.3.125 Published online September 30, 2013.

글루카곤양펩티드-1 (GLP-1) 유사체의 임상효과

전현지, 권혁상

Clinical Efficacy of Glucagon Like Peptide-1 (GLP-1) Analogues.

Hyun Ji Chun, Hyuk Sang Kwon

Department of Internal Medicine, Division of Endocrinology and Metabolism, The Catholic University of Korea, Seoul, Korea. drkwon@catholic.ac.kr

Abstract

Recently, incretin hormone-based therapies, including glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors, have become the main therapeutic tools in the hyperglycemia management in patients with type 2 diabetes mellitus. These therapeutic agents could fill an important gap in glycemic control for patients with type 2 diabetes because the incretin response is blunted in type 2 diabetes mellitus. GLP-1 analogues can be classified as exendin-4 backbone (Exenatide, Exenatide LAR and Lixisenatide) and human GLP-1 backbone (Liraglutide, Taspoglutide and Albiglutide). Among these, Exenatide, Exenatide LAR and Liraglutide are currently available. This review will focus on the clinical efficacies of GLP-1 analogues in glycemic control for patients with diabetes.

Key Words: Type 2 diabetes mellitus, GLP-1 analogues, Incretins